Bringing hope, innovation and personalized care to cancer patients worldwide
Bringing hope, innovation and personalized care to cancer patients worldwide

Clinical Trials Available at GCRI

All Solid Tumor Patients:

  • A Phase I/II Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

Bladder Cancer:

  • A Phase II Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Bladder Cancer

Breast Cancer:

  • A Phase III Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with HER2+ Metastatic Breast Cacner Who Have Received Two or More Prior HER2+ Directed Regimes in the Metastatic Setting (NALA)
  • A Phase III Trial of Niraparib Versus Physician's Choice in HER2-ve, Germline BRCA Mutation Positive Breast Cancer Patients (BRAVO)

Colon Cancer:

  • Prospective International Observational Cohort Non-Comparative Study Describing the Safety and Effectiveness of ZALTRAP Administered in Combination with FOLFIRI for the Treatment of Patients with Metastatic Colorectal Cancer in Current Clinical Practice: A Post-Authorisation Safety Study (OZONE)
  • TAS-102 Expanded Access Program for Patients with Colon Cancer Who Have Failed 5FU, Oxaliplatin and Irinotecan-Based Therapy

Lung Cancer:

  • A Multicentre, Randomized, Double-Blind, Phase III Trial to Investigate the Efficacy and Safety of Oral Nintedanib Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients with Stage IIIB/IV or Recurrent, Adenocarcinoma Subtype Non-Small Cell Lung Cancer After Failure of First Line Chemotherapy
  • Safety and Efficacy of Nab-Paclitaxel (Abraxane) in Combination with Carboplatin as First Line Treatment in Elderly Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, MultiCetner Study (ABOUND.70+)
  • A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 antibody) in Combination with Carboplatin+Paclitaxel or MPDL3280A in Combination with Carboplatin+Nab-Paclitazel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients with Stage IV Squamous Non-Small Cell Lung Cancer
  • A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 antibody) in Combination with Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplaitn+Paclitaxel+Bevacizumab in Chemotherapy-Naive Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Pancreatic Cancer:

  • A Randomized, Double-Blind, Phase III Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (JANUS 1)
  • A Phase II Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer

Lymphoma:

  • A Phase III, Randomized, Double-Blind Study of PF-05280586 Versus Rituximab for First-Line Treatment of Patients with CD20+, Low Tumor Burder, Follicular Lymphoma (REFLECTIONS B3281006)
  • A Randomized, Double-Blind, Placebo-Controlled Phase III Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination with Eitehr Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubincin, Vincristine, and Prednisone (R-CHOP) in Subjects with Previously Treasted Indolent Non-Hodgkin Lymphoma (iNHL) (SELENE)

Multiple Myeloma:

  • A Phase III, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation
  • A Phase III Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy

 

To Schedule An Appointment, Contact Us Today!

MON TO FRI 9AM to 5PM

info@gcrioncology.com

2 locations to serve you:

 

9460 No Name Uno Ste 230

Gilroy, CA 95020

408-847-6191

408-847-6196 fax

 

2242 Camden Ave, Ste 203

San Jose, CA 95124

408-384-9284

408-847-6196 fax

Like us on Facebook

Print Print | Sitemap
© www.gcrioncology.com | info@gcrioncology.com